Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)
Recruiting
18-99 years
All
Phase
3
1000 participants needed
1 Location
Brief description of study
This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events (MACE) in subjects with Acute Coronary Syndrome (diagnosed with STEMI or NSTEMI), who are receiving evidence-based medical therapy.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Acute Coronary Syndrome
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female, Age 18 or older, Evidence of myocardial necrosis, consistent with type I (spontaneous) MI
Updated on
09 Mar 2024.
Study ID: 829891
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting